Objectives: The objective of this study was to characterize the underlying molecular mechanisms in consecutive clinical Candida albicans isolates from a single patient displaying stepwise-acquired multidrug resistance.
Introduction
Candida albicans is inherently susceptible to all antifungal drugs. Monoresistance to azoles or echinocandins and a few cases of combined azole and amphotericin B resistance have been reported, but multidrug resistance covering all three drug classes is a rare and, to our knowledge, previously unreported phenomenon in C. albicans. 1 Azole resistance in C. albicans is often an interplay of: (i) structural changes of Erg11 (14a-methyl sterol demethylase), the target of azoles; (ii) overexpression of ERG11; and (iii) increased cellular export of azoles by up-regulated drug efflux transporters. 2 The genetic regulation of azole resistance involves ERG11 up-regulation linked to specific gain-of-function (GOF) mutations in zinc cluster transcription factor UPC2 3 as well as increases in copy number due to isochromosome formation or duplication of chromosome 5. 4 Likewise, GOF mutations in transcription factors TAC1 and MRR1 lead to up-regulation of drug efflux pumps CDR1/CDR2 and MDR1, respectively. 5 Acquired echinocandin resistance in C. albicans has been linked to structural alterations of the target enzyme Fks1 (1,3-b-D-glucan synthase), which is essential for cell wall synthesis. 6 Resistance to polyenes in C. albicans is rare, but has been linked to inactivation of essential proteins in ergosterol biosynthesis leading to ergosterol depletion (the target of amphotericin B) and the formation of other sterols. Here, we present a detailed molecular assessment of the underlying genetic mechanisms contributing to the sequential development of unique MDR strains by evaluation of consecutive C. albicans isolates from a single patient.
Brief case report
A man in his early sixties with angioimmunoblastic T cell lymphoma underwent stem cell transplantation in 2006 followed by long-term pancytopenia and recurrent infections including numerous episodes of oropharyngeal and oesophageal candidiasis despite various courses of antifungal treatment ( Figure S1 , available as Supplementary data at JAC Online). Increasingly resistant C. albicans isolates were found in oesophageal and colon biopsies and faeces before the patient died in 2011.
Materials and methods

Strains and susceptibility testing
Nine clinical isolates obtained in 2006 -11 underwent susceptibility testing at the Statens Serum Institut according to EUCAST EDef 7.2 (azoles and anidulafungin) and by Etest (amphotericin B and caspofungin). Susceptibility was interpreted by using the established EUCAST breakpoints (http://www.eucast.org/clinical_breakpoints/) and CLSI breakpoints for Etests. 8 -11 Sequencing and gene expression analysis Five isolates (P-4, P-5, P-7, P-8 and P-9) were available for molecular analyses (Table 1) . MLST was performed as described previously 12 and additional genes were sequenced (notably FKS1, ERG11, ERG2, UPC2 and TAC1). 13 -15 Gene expression analysis was performed for ERG11 and drug efflux pumps CDR1 and CDR2 by RNA quantification using quantitative PCR (qPCR) as described previously. 15 All primers used in this study are provided in Table S1 .
Sterol composition
Sterol analysis was performed by: (i) spectrophotometric UV absorption profiles on non-saponifiable fractions of lipids extracted with n-heptane through vigorous vortex agitation by a simplified protocol from a previous study and measured between 240 and 320 nm; 16 and (ii) GC-MS. Sterols were extracted with NaOH and methanol at 908C and further by pentane phase separation and dissolved in 2-propanol. Next, 50 mL of the extract was further evaporated to dryness, derivatized to trimethylsilyl ethers and analysed as described previously. 17 Virulence determination in the Galleria mellonella larvae model
Virulence was evaluated in the insect model G. mellonella caterpillars as described previously. 18 Caterpillars (250 -325 mg, HPReptiles, Copenhagen, Denmark) were inoculated in groups of 20 or 25 and the inocula were standardized to achieve an 80% mortality of WT isolates within 5 days ( 5×10 5 cells/larvae). Caterpillars were incubated at 378C for up to 5 days after inoculation. Groups were compared using the log-rank Mantel -Cox test (Prism 6.05, GraphPad). P values of ,0.05 were considered significant.
Results and discussion
Antifungal treatment and susceptibility profiles
During long-term antifungal treatment ( Figure S1 ), antifungal resistance emerged in a stepwise manner (Table 1) . Fluconazole resistance was found in P-3 (after a total of 34 weeks of fluconazole therapy), pan-azole resistance in P-5 (after 8 weeks of voriconazole and 96 weeks of posaconazole exposure), echinocandin resistance in P-6 (after 6 weeks of caspofungin and anidulafungin exposure) and, finally, multidrug resistance emerged in P-8 (after 9 weeks of either nystatin or amphotericin B treatment).
MLST analysis
Identical diploid STs were found for isolates P-7, P-8 and P-9 (21-26-14-19-72-102-84), suggesting that they were isogenic. P-4 (21-26-14-18-76-102-84) and P-5 (21-26-14-18-72-102-84) deviated in the MP1b and SYA1 alleles. When including additional sequenced genes such as FKS1, ERG11 and ERG2 in an expanded MLST analysis, there was an even stronger hereditary link suggesting a common progenitor and the stepwise selection of isogenic MDR offspring.
Fluconazole resistance
Among four amino acid changes identified in Erg11 of the fluconazole-resistant isolate P-4 (Table 1 ), G307S and G450E have previously been associated with fluconazole resistance and confirmed in genetically engineered C. albicans. 19 Hence, these mutations may have been significant drivers of fluconazole resistance in P-4 and probably further potentiated by elevated expression levels of ERG11 and particularly CDR2 (Table 1) .
Pan-azole resistance
Subsequent pan-azole-resistant clinical isolates possessed an additional alanine to glutamic acid change (A61E) in Erg11 (Table 1) . A61E is novel, but involves a codon (A61V) previously indicated to slightly impact binding of and susceptibility to itraconazole and posaconazole. 20 Compared with the A61V alteration, a change from the hydrophobic alanine to the acidic and much larger glutamic acid found here would be expected to have a stronger effect on interference with long-tailed azoles. Protein modelling ( Figure S2 ) illustrates steric interference of A61E with the tail of itraconazole and thus is consistent with this hypothesis, although independent validation remains necessary. Overexpression of ERG11 (except for P-7), CDR1 and CDR2 may have contributed to azole resistance, especially to voriconazole in P-5 through P-9.
Elevated gene expression and genetic precursors
ERG11 up-regulation may have been a compensatory mechanism (independent of UPC2 mutations) to avoid ergosterol depletion associated with the potentially reduced catalytic activity of the Erg11 variants. 21, 22 CDR1 and especially CDR2 up-regulation was detected in high relative levels in all azole-resistant clinical isolates (Table 1) . TAC1 sequencing revealed a novel amino acid change (R688Q) in P-4. Whether this alteration mediated the up-regulation particularly of CDR2 in P-4 deserves further investigation. 23 The allelic state of TAC1 was heterozygous in P-4, but homozygous in P-5 through P-9; thus, it is likely that the TAC1 locus underwent a 'loss of heterozygosity' from P-4 to P-5, which is a phenomenon frequently associated with azole resistance. 4 Additionally, another novel TAC1 change (R673L) was found in P-5 through P-9 (Table 1) , which displayed even higher expression levels of CDR1 and CDR2, indicating the potential of another novel GOF variant and should be independently validated in future studies. 24 
Echinocandin resistance and FKS1 mutations
Echinocandin-resistant clinical isolates harboured a (heterozygous) mutation in FKS1 leading to the amino acid change S645P (Table 1) , which is well known to confer high-level echinocandin resistance. 25 
Amphotericin B resistance
Sequencing of essential genes in the ergosterol biosynthetic pathway revealed a heterozygous frameshift mutation in ERG2 (encoding D 8 7 isomerase) at amino acid position Phe-105 (F105SfsX23) in P-7, but homozygous in the amphotericin B-resistant isolates P-8 and P-9. This caused a truncated protein sequence reduced from 217 to 126 amino acids (Table 1) , which may presumably be associated with protein function inactivation. In support, an amino acid disruption in Erg2 corresponding to Thr-115 in C. albicans was critical for sterol D 8 7 isomerization in other Candida species. 26, 27 GC-MS analysis showed that P-8 and P-9 were depleted of ergosterol and instead displayed an accumulation of ergosta-8-enol, ergosta-8,22-dienol, ergosta-5,8,22-trienol and fecosterol as well as a few other sterols (Figure 1 ). This sterol profile matches previous findings involving ERG2 deletion mutants. 26, 28 Thus, although supported by the literature, an independent validation is necessary to address whether the ERG2 mutation alone is able to confer polyene resistance.
Virulence of the resistant isolates
Acquired resistance in C. albicans may come at a fitness and virulence cost. 15, 29, 30 The two susceptible control strains C-1 and C-2 were equally virulent (P ¼ 0.2) and resulted in day 5 mortality of 88% and 98%, respectively ( Figure 1 ). P-4 was statistically less MDR Candida albicans 2553 JAC virulent than both WT control isolates, but all clinical isolates were significantly more virulent than an unrelated azole-and echinocandin-resistant control strain C-3 (displaying 51% overallmortality). The virulence of the clinical isogenic isolates was only slightly reduced compared with that of the susceptible control strains, indicating that compensatory mechanisms may have abrogated virulence cost in these MDR isolates.
Conclusions
Here, we presented a suite of well-known and novel genetic mechanisms contributing to the sequential development of resistance to all three antifungal drug classes, which to the best of our knowledge is the first example of multidrug resistance emerging in vivo in C. albicans. Interestingly, the observed resistance came without significant virulence cost. The superficial nature of the infection, where subtherapeutic concentrations are more common, may have facilitated the emergence of resistance. Our study is associated with several limitations. Most importantly, we did not have the initial susceptible clinical isolates as such superficial WT strains are not routinely stored. Secondly, we have addressed and argued for several potential resistance mechanisms and hypothesized novel findings supported by existing knowledge. However, the significance of these findings requires independent validation. Figure S1 , Table S1 and Figure S2 are available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
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